KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Amortization of Deferred Charges (2016)

Charles River Laboratories International (CRL) has 7 years of Amortization of Deferred Charges data on record, last reported at $506000.0 in Q4 2016.

  • For Q4 2016, Amortization of Deferred Charges rose 23.41% year-over-year to $506000.0; the TTM value through Dec 2016 reached $2.8 million, up 18.95%, while the annual FY2016 figure was $2.8 million, 18.95% up from the prior year.
  • Amortization of Deferred Charges reached $506000.0 in Q4 2016 per CRL's latest filing, up from $34000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $4.6 million in Q1 2013 and bottomed at $34000.0 in Q3 2016.
  • Average Amortization of Deferred Charges over 5 years is $1.7 million, with a median of $436000.0 recorded in 2013.
  • Peak YoY movement for Amortization of Deferred Charges: surged 165.36% in 2015, then crashed 91.46% in 2016.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $4.5 million in 2012, then tumbled by 90.26% to $437000.0 in 2013, then dropped by 2.29% to $427000.0 in 2014, then decreased by 3.98% to $410000.0 in 2015, then increased by 23.41% to $506000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $506000.0 in Q4 2016, $34000.0 in Q3 2016, and $1.9 million in Q2 2016.